Compare Prudential PLC (PUK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Spyre Therapeutics Inc. Common Stock — how do they compare? Prudential PLC trades at $23.69 (market cap $29.00B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Prudential PLC is far larger — about 3.9× Spyre Therapeutics Inc. Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PUK | SYRE | |
|---|---|---|
Market Cap | $29.00B | $7.52B |
Volume | 1,133,946 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $33.61 | $108.92 |
52-Week Low | $23.54 | $22.18 |
Typical Hold Time | 119 Days | 0 Days |
Enterprise Value | $28.54B | $6.52B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Public Limited Company (PUK) trades at $23.81, down 0.25% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company demonstrates strong fundamentals with $27.39B revenue in 2025, 12.27% net income margin, and attractive valuation metrics including an 8.38 P/E ratio. Recent earnings show two beats and two misses in the last four quarters, while analyst sentiment remains moderately positive with 50% buy ratings.
PUK presents a compelling value opportunity with strong profitability and growth in Asian markets, though near-term technical weakness and emerging market exit execution risks warrant caution. The stock's current valuation discount to peers and consistent dividend payments provide downside protection, while strategic refocusing on core markets could drive long-term shareholder value.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
